APA (7th ed.) Citation

I, C., GD, K., S, d. P., D, P., F, P., E, A., & S, D. F. (2018). Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: Impact on clinical status, substance craving, and quality of life. Dove Medical Press.

Chicago Style (17th ed.) Citation

I, Cuomo, Kotzalidis GD, de Persis S, Piacentino D, Perrini F, Amici E, and De Filippis S. Head-to-head Comparison of 1-year Aripiprazole Long-acting Injectable (LAI) Versus Paliperidone LAI in Comorbid Psychosis and Substance Use Disorder: Impact on Clinical Status, Substance Craving, and Quality of Life. Dove Medical Press, 2018.

MLA (8th ed.) Citation

I, Cuomo, et al. Head-to-head Comparison of 1-year Aripiprazole Long-acting Injectable (LAI) Versus Paliperidone LAI in Comorbid Psychosis and Substance Use Disorder: Impact on Clinical Status, Substance Craving, and Quality of Life. Dove Medical Press, 2018.